Recent advances in bladder cancer treatments may offer hope of curative care to more patients, including those with high-risk ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

BioNTech’s willingness to significantly increase its upfront bet on BNT327 reflects a belief the candidate could set a new ...

A research team has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell ...

Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...

Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...

If you frequently wake up to go to the bathroom during the night, you may have nocturia. Nocturia refers to having an overactive bladder at night, and can be frustrating and difficult to live with – ...

in combination with Keytruda, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with resectable Stage II, IIIA or IIIB non-small cell lung cancer who did not achieve a pathological ...

The INTerpath-009 trial will investigate an individualized neoantigen therapy plus Keytruda in patients with non-small cell lung cancer post-surgery whose disease didn't fully respond to prior ...

NEW YORK – Moderna and Merck will test their personalized neoantigen cancer vaccine V940 with Merck's checkpoint inhibitor Keytruda (pembrolizumab) in certain non-small cell lung cancer patients in a ...